Phospho-TNK2 (Tyr284) Antibody

What is TNK2 and what is the significance of its phosphorylation at Tyr284?

TNK2 (Tyrosine Kinase Non-Receptor Protein 2), also known as ACK1 (Activated Cdc42 Kinase 1), is a non-receptor tyrosine and serine/threonine protein kinase involved in multiple cellular processes. It plays critical roles in cell spreading, migration, survival, growth, and proliferation, serving to transduce extracellular signals to cytosolic and nuclear effectors. The protein phosphorylates several substrates including AKT1, AR, MCF2, WASL, and WWOX .

Phosphorylation at Tyr284 is particularly important as it represents a primary activating tyrosine residue. This specific phosphorylation event is crucial for TNK2 activation, with the kinase SRC implicated as a possible upstream kinase that phosphorylates this site . The Tyr284 phosphorylation serves as a molecular switch that regulates TNK2's kinase activity and its subsequent downstream signaling capabilities.

Where is phosphorylated TNK2 (Tyr284) localized within cells?

The Tyr284 phosphorylated form of TNK2 exhibits a distinct subcellular distribution pattern. According to research data, phospho-TNK2 (Tyr284) is found in both the cell membrane and nucleus . Its specific locations include:

• Cell membrane

• Nucleus

• Endosomes

• Cell junctions (particularly adherens junctions)

• Cytoplasmic vesicle membranes (as a peripheral membrane protein on the cytoplasmic side)

• Clathrin-coated vesicles

• Clathrin-coated pits of the membrane

Notably, TNK2 colocalizes with EGFR (Epidermal Growth Factor Receptor) on endosomes, and its nuclear translocation is CDC42-dependent . This distinct localization pattern is important for understanding the context-specific functions of the activated form of TNK2.

How does Phospho-TNK2 (Tyr284) expression correlate with cancer progression?

The phosphorylated form of TNK2 at Tyr284 shows a significant relationship with cancer progression. Multiple studies have documented that phospho-TNK2 (Tyr284) expression increases progressively through the stages of both breast and prostate cancers .

In breast cancer, phospho-TNK2 (Tyr284) expression increases during the following progressive stages:

• Normal breast tissue

• Atypical ductal hyperplasia (ADH)

• Ductal carcinoma in situ (DCIS)

• Invasive ductal carcinoma (IDC)

• Lymph node metastatic (LNMM) stages

Similarly, increased expression is observed during the progressive stages of prostate cancer development . This correlation suggests that phospho-TNK2 (Tyr284) may serve as a potential biomarker for cancer progression and could represent a therapeutic target in advanced cancers.

What are the validated research applications for Phospho-TNK2 (Tyr284) antibodies?

Phospho-TNK2 (Tyr284) antibodies have been validated for multiple research applications, allowing for comprehensive investigation of this phosphorylation event across various experimental contexts. The applications include:

These applications enable researchers to study phospho-TNK2 (Tyr284) at multiple levels, from protein quantification to visualization of its spatial distribution within cells and tissues .

What is the optimal protocol for detecting Phospho-TNK2 (Tyr284) in Western blot experiments?

For optimal detection of phospho-TNK2 (Tyr284) in Western blot experiments, the following protocol is recommended based on validated research applications:

• Sample preparation: Lyse cells in a buffer containing phosphatase inhibitors to preserve phosphorylation status. HepG2 cells treated with EGF (200 ng/ml for 30 minutes) have been demonstrated as a positive control model system .

• Protein separation: Separate proteins using SDS-PAGE (typically 8-10% gels are suitable for TNK2's molecular weight).

• Transfer: Transfer proteins to PVDF or nitrocellulose membranes using standard techniques.

• Blocking: Block the membrane with 5% BSA in TBST (not milk, as it contains phosphatases that may reduce signal).

• Primary antibody incubation: Dilute phospho-TNK2 (Tyr284) antibody at 1:500-1:2000 in blocking buffer and incubate overnight at 4°C .

• Washing: Wash the membrane 3-5 times with TBST.

• Secondary antibody: Incubate with appropriate HRP-conjugated secondary antibody.

• Detection: Visualize using enhanced chemiluminescence.

For validation purposes, it is advisable to include a phospho-peptide blocking control, which has been shown to effectively block the specific signal, confirming antibody specificity .

How can researchers effectively use Phospho-TNK2 (Tyr284) antibodies in immunohistochemistry of cancer tissues?

For effective immunohistochemistry (IHC) studies of phospho-TNK2 (Tyr284) in cancer tissues, researchers should follow these methodological guidelines:

• Tissue preparation: Use formalin-fixed, paraffin-embedded (FFPE) tissue sections. Human breast carcinoma tissues have been successfully used for phospho-TNK2 (Tyr284) detection .

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 8.0). This step is crucial for exposing the phospho-epitope that may be masked during fixation.

• Blocking: Block endogenous peroxidase activity and non-specific binding sites.

• Primary antibody: Apply phospho-TNK2 (Tyr284) antibody at a dilution of 1:100-1:300 and incubate according to the manufacturer's recommendation (typically overnight at 4°C) .

• Detection system: Use an appropriate detection system (e.g., HRP-polymer) followed by DAB chromogen visualization.

• Counterstaining: Counterstain with hematoxylin to visualize tissue architecture.

• Controls: Always include both positive controls (breast carcinoma tissue) and negative controls. For specificity validation, include a phospho-peptide blocking control, which should eliminate specific staining .

When analyzing results, researchers should pay particular attention to both membrane and nuclear localization of phospho-TNK2 (Tyr284), as both compartments show staining in cancer tissues .

How does Phospho-TNK2 (Tyr284) interact with PTPN11 in signaling pathways?

Phospho-TNK2 (Tyr284) and PTPN11 (also known as SHP2) engage in a complex reciprocal regulatory relationship that influences downstream MAPK pathway signaling. Research has revealed several important aspects of this interaction:

• TNK2 phosphorylates PTPN11: TNK2 acts as an upstream activator of PTPN11 by phosphorylating it at Tyr542 and Tyr580 residues. This phosphorylation event activates PTPN11, enabling it to enhance downstream MAPK signaling .

• PTPN11 dephosphorylates TNK2: Conversely, PTPN11 dephosphorylates TNK2 at its activating Tyr284 residue. This dephosphorylation is particularly pronounced with mutant PTPN11 compared to wild-type PTPN11 .

• Feedback regulatory mechanism: This creates a feedback loop where TNK2 phosphorylates and activates PTPN11, which in turn deactivates TNK2 through dephosphorylation, creating a self-regulating signaling circuit .

• MAPK pathway activation: The coexpression of PTPN11 (especially the E76K mutant) and TNK2 results in significant increases in phosphorylated p44/42 MAPK, indicating enhanced MAPK pathway activation .

• Drug interventions: Both TNK2 inhibitors (like dasatinib and XMD8-87) and PTPN11 inhibitors (like SHP099) can disrupt this regulatory circuit. TNK2 inhibition reduces PTPN11 phosphorylation, while PTPN11 inhibition increases TNK2 phosphorylation while decreasing MAPK signaling .

This complex interaction has significant implications for understanding signaling in cancer cells and potentially developing targeted therapies.

What is the relationship between SRC kinase and TNK2 phosphorylation at Tyr284?

The relationship between SRC kinase and TNK2 phosphorylation at Tyr284 is particularly important for understanding the activation mechanism of TNK2. According to research findings:

• SRC as an upstream kinase: SRC has been implicated as a possible kinase responsible for phosphorylating TNK2 at the Tyr284 residue . This phosphorylation event is critical for TNK2 activation.

• Activation mechanism: The phosphorylation of TNK2 at Tyr284 by SRC serves as a key step in the activation of TNK2's intrinsic kinase activity, enabling it to phosphorylate its downstream substrates.

• Context-specific activation: The SRC-mediated phosphorylation of TNK2 at Tyr284 can be induced in specific cellular contexts, such as EGF stimulation, as demonstrated in the HepG2 cell model where EGF treatment (200 ng/ml for 30 minutes) led to increased phosphorylation of TNK2 at Tyr284 .

• Feedback regulation: Once activated through Tyr284 phosphorylation, TNK2 participates in feedback regulatory mechanisms involving other signaling proteins, including PTPN11, which can subsequently modulate the phosphorylation status of TNK2 .

Understanding this relationship is crucial for researchers studying the activation mechanisms of TNK2 and its role in various signaling pathways, particularly those relevant to cancer progression.

How does TNK2 phosphorylation affect EGFR trafficking and signaling?

TNK2 phosphorylation, particularly at Tyr284, plays a significant role in EGFR trafficking and signaling through several mechanisms:

• Colocalization with EGFR: The phosphorylated form of TNK2 (Tyr284) colocalizes with EGFR on endosomes, suggesting a direct role in EGFR trafficking and processing .

• Clathrin-mediated endocytosis: TNK2 is implicated in trafficking and clathrin-mediated endocytosis through binding to EGFR and clathrin . Phosphorylation of TNK2 at Tyr518 (a different site) has been observed during association with clathrin-coated pits, which may work in concert with Tyr284 phosphorylation .

• EGFR regulation: TNK2 can be activated downstream of EGFR, as demonstrated by the increased phosphorylation of TNK2 at Tyr284 following EGF treatment of HepG2 cells .

• Signal transduction: Activated TNK2 transduces extracellular signals (such as those initiated by EGF binding to EGFR) to cytosolic and nuclear effectors, affecting downstream signaling cascades .

• Degradation regulation: TNK2 degradation can be induced by EGF and is lysosome-dependent, suggesting a regulatory loop where EGFR signaling ultimately controls TNK2 levels. Additionally, TNK2 is polyubiquitinated by NEDD4 and NEDD4L, which may affect its stability and function in EGFR trafficking .

These findings indicate that phosphorylated TNK2 serves as an important mediator in EGFR trafficking and signaling, with implications for understanding growth factor signaling in both normal and cancer cells.

How does Phospho-TNK2 (Tyr284) expression change across cancer progression stages?

Phospho-TNK2 (Tyr284) expression exhibits a clear pattern of progressive increase through cancer development stages, making it a potential biomarker for disease progression. Research has documented specific patterns in both breast and prostate cancers:

In breast cancer, phospho-TNK2 (Tyr284) expression increases sequentially through the following stages:

• Normal breast tissue (baseline expression)

• Atypical ductal hyperplasia (ADH) (initial increase)

• Ductal carcinoma in situ (DCIS) (further elevation)

• Invasive ductal carcinoma (IDC) (significant elevation)

• Lymph node metastatic (LNMM) stages (highest expression levels)

Similarly, a progressive increase in phospho-TNK2 (Tyr284) expression is observed during prostate cancer development and progression . This consistent upregulation across increasing stages of malignancy suggests that phospho-TNK2 (Tyr284) may be actively involved in driving cancer progression rather than merely being a passive biomarker.

The consistent pattern across two different cancer types (breast and prostate) further supports the hypothesis that TNK2 phosphorylation at Tyr284 may represent a common mechanism in epithelial cancer progression, potentially making it both a valuable diagnostic marker and therapeutic target.

What is the mechanism of synthetic lethality between TNK2 inhibition and PTPN11 mutations in leukemia?

The synthetic lethality between TNK2 inhibition and PTPN11 mutations in leukemia represents a significant therapeutic opportunity based on the reciprocal regulatory relationship between these proteins. The mechanism involves several key components:

This synthetic lethality paradigm provides a rational basis for targeting TNK2 in PTPN11-mutant leukemias and potentially other cancers with similar pathway alterations.

How can researchers use Phospho-TNK2 (Tyr284) antibodies to evaluate the efficacy of kinase inhibitors in cancer models?

Researchers can employ phospho-TNK2 (Tyr284) antibodies as effective tools to evaluate the efficacy of kinase inhibitors in cancer models through several methodological approaches:

• Direct target engagement assessment: Western blot analysis using phospho-TNK2 (Tyr284) antibodies can directly assess whether TNK2 inhibitors (such as dasatinib or XMD8-87) are effectively blocking TNK2 phosphorylation at Tyr284. This provides evidence of on-target activity of the inhibitors .

• Downstream signaling evaluation: Since phosphorylated TNK2 activates PTPN11 (by phosphorylating it at Tyr542 and Tyr580), researchers can use phospho-TNK2 (Tyr284) antibodies in conjunction with phospho-PTPN11 antibodies to evaluate the effects of inhibitors on this signaling axis .

• Pathway inhibition assessment: Measuring MAPK pathway activity (phospho-p44/42 MAPK levels) alongside phospho-TNK2 (Tyr284) levels can determine whether inhibition of TNK2 phosphorylation correlates with desired downstream pathway inhibition .

• In vitro to in vivo correlation: Researchers can use phospho-TNK2 (Tyr284) antibodies in both cell-based assays (Western blot, immunocytochemistry) and tissue-based analyses (immunohistochemistry) to track inhibitor efficacy across different experimental systems and determine whether in vitro efficacy translates to in vivo models .

• Resistance mechanism identification: In models developing resistance to TNK2 inhibitors, phospho-TNK2 (Tyr284) antibodies can help determine whether resistance occurs through maintained TNK2 phosphorylation (suggesting incomplete target inhibition) or through bypass mechanisms (where TNK2 remains inhibited but downstream signaling is reactivated) .

These applications make phospho-TNK2 (Tyr284) antibodies valuable tools in both basic research on kinase inhibitor mechanisms and translational research aimed at developing new therapeutic strategies for cancers with aberrant TNK2 signaling.

What are the key factors affecting specificity and sensitivity when detecting Phospho-TNK2 (Tyr284) in different experimental systems?

Several critical factors influence the specificity and sensitivity of phospho-TNK2 (Tyr284) detection across different experimental platforms:

• Antibody selection: Different commercially available phospho-TNK2 (Tyr284) antibodies may have varying specificity profiles. Those raised against synthetic phosphopeptides corresponding to the sequence around Tyr284 (such as D-H-Y(p)-V-M) typically show higher specificity .

• Phosphatase activity: Sample preparation must include appropriate phosphatase inhibitors to preserve the phosphorylation status. This is particularly important for cell and tissue lysates where endogenous phosphatases can rapidly dephosphorylate TNK2 .

• Epitope masking: In fixed tissues (IHC) and cells (ICC/IF), proper antigen retrieval is essential as formalin fixation can mask the phospho-epitope. Citrate or EDTA-based antigen retrieval methods have proven effective .

• Blocking controls: For validation of specificity, phospho-peptide blocking controls should be employed. When the antibody is pre-incubated with the phosphopeptide immunogen, specific staining should be eliminated, as demonstrated in both Western blot and IHC applications .

• Signal amplification: For low-abundance phosphorylation events, signal amplification methods may be necessary, especially in IHC applications. Tyramide signal amplification can enhance sensitivity while maintaining specificity .

• Cell stimulation: To increase detection sensitivity, stimulating cells with EGF (200 ng/ml for 30 minutes) has been shown to enhance TNK2 phosphorylation at Tyr284, making it a useful positive control condition for antibody validation and experimental standardization .

• Cross-reactivity assessment: Potential cross-reactivity with other phosphorylated tyrosine residues should be evaluated, particularly in contexts where multiple tyrosine kinases are activated. Specific phospho-peptide competition assays can help distinguish specific from non-specific signals .

Understanding and controlling these factors is essential for generating reliable and reproducible data when studying phospho-TNK2 (Tyr284) across different experimental systems.

How can researchers distinguish between Tyr284 phosphorylation and other post-translational modifications of TNK2?

Distinguishing between phosphorylation at Tyr284 and other post-translational modifications of TNK2 requires specific methodological approaches:

• Phospho-specific antibodies: Use antibodies that specifically recognize TNK2 phosphorylated at Tyr284, such as those developed against synthetic phosphopeptides containing the sequence around this residue (e.g., D-H-Y(p)-V-M) . These antibodies should not cross-react with other phosphorylation sites.

• Phospho-peptide competition assays: Perform parallel experiments where the antibody is pre-incubated with the specific phospho-peptide used as the immunogen. Specific phospho-Tyr284 signal should be eliminated by this competition, while signals from other modifications would remain .

• Mutagenesis studies: In research contexts where protein expression constructs are used, compare wild-type TNK2 with Y284F mutants that cannot be phosphorylated at this position but can still undergo other modifications. This allows for clear distinction between Tyr284-specific events and other modifications .

• Mass spectrometry: For comprehensive analysis of TNK2 post-translational modifications, mass spectrometry can definitively identify and quantify site-specific phosphorylation at Tyr284 while simultaneously detecting other modifications such as ubiquitination (TNK2 is known to be polyubiquitinated by NEDD4 and NEDD4L) .

• Kinase and phosphatase inhibitor profiles: Different phosphorylation sites on TNK2 may be regulated by distinct kinases and phosphatases. For example, SRC is implicated in Tyr284 phosphorylation , while PTPN11 appears to dephosphorylate this site . Using specific inhibitors can help distinguish the regulation of different modification sites.

• Multi-antibody approach: Use multiple antibodies targeting different modifications of TNK2 in parallel experiments. For instance, comparing phospho-Tyr284 with phospho-Tyr518 (which is associated with clathrin-coated pits) can provide insights into the distinct functions of different phosphorylation events.

By employing these approaches, researchers can effectively differentiate Tyr284 phosphorylation from other post-translational modifications of TNK2, enabling more precise understanding of the specific roles of each modification in TNK2 function.

What are the best experimental approaches to study the functional consequences of TNK2 phosphorylation at Tyr284?

To effectively study the functional consequences of TNK2 phosphorylation at Tyr284, researchers can employ several complementary experimental approaches:

• Phospho-mimetic and phospho-dead mutations: Generate TNK2 constructs with Y284E/D mutations (phospho-mimetic) or Y284F mutations (phospho-dead) for expression studies. Comparing the activity and downstream effects of these mutants with wild-type TNK2 can directly link Tyr284 phosphorylation to specific cellular functions .

• Kinase activity assays: Measure the intrinsic kinase activity of TNK2 before and after inducing phosphorylation at Tyr284 (e.g., through EGF stimulation). In vitro kinase assays using immunoprecipitated TNK2 can determine whether Tyr284 phosphorylation directly affects its catalytic activity toward substrates like PTPN11 .

• Proximity-based proteomics: Employ BioID or APEX2-based proximity labeling with wild-type vs. Y284F mutant TNK2 to identify interaction partners that specifically recognize the phosphorylated form, providing insights into phosphorylation-dependent protein-protein interactions.

• Subcellular localization studies: Use immunofluorescence with phospho-TNK2 (Tyr284) antibodies to track the localization of the phosphorylated form compared to total TNK2. This approach can reveal whether Tyr284 phosphorylation influences trafficking between cellular compartments, particularly given the known localization of phospho-TNK2 (Tyr284) in both membrane and nuclear compartments .

• Signaling pathway analysis: Monitor downstream signaling events (particularly MAPK pathway activation) in response to manipulation of TNK2 Tyr284 phosphorylation status. This can be achieved using specific inhibitors of upstream kinases (like SRC inhibitors) or expression of phospho-mutants .

• Cancer model systems: Since phospho-TNK2 (Tyr284) shows increased expression in progressive stages of breast and prostate cancers , employing cancer cell lines, organoids, or animal models representing different disease stages can provide physiologically relevant contexts for studying the functional consequences of this phosphorylation.

• Synthetic lethality screening: Building on the established synthetic lethality between TNK2 inhibition and PTPN11 mutations in leukemia , researchers can screen for additional genetic or pharmacological contexts where TNK2 Tyr284 phosphorylation becomes critical for cell survival or function.

By combining these approaches, researchers can build a comprehensive understanding of how Tyr284 phosphorylation regulates TNK2 function in both normal physiology and disease states.